Table 1.

Overview of identified neoantigens

PatientNumber of tier 1 mutationsaNumber of mutations expressedbNumber predicted to bindcNumber actually binding/testeddNumber immunogenic in vitroeNumber conferring tumor recognitionf
  • aAs determined by whole-exome sequencing and from each patient xenograft.

  • bAs determined by cDNA Cap-Seq and other filters described in Materials and Methods.

  • cAs determined by NetMHC 3.2 (affinity of mutant peptides < 500 nmol/L).

  • dBinding assay evaluated using the T2 assay.

  • eReactivity as determined by IFNγ ELISPOT assay in vitro as described in Materials and Methods.

  • fReactivity as determined by tumor growth inhibition in the NSG mouse model in vivo as described in Materials and Methods.